Literature DB >> 10626347

Modifying the properties of platinum (IV) complexes in order to increase biological effectiveness.

T W Hambley1, A R Battle, G B Deacon, E T Lawrenz, G D Fallon, B M Gatehouse, L K Webster, S Rainone.   

Abstract

The preparation of a series of novel Pt(IV) complexes containing the anionic polyfluoroaryl ligands, 2,3,5,6-tetrafluorophenyl (p-HC6F4), 2,3,5,6-tetrafluoro-4-methoxyphenyl (p-MeOC6F4) and pentafluorophenyl (C6F5) are described. The crystal structure of a representative complex, [Pt(p-MeOC6F4)2(O2CEt)2(en)] (en = ethane-1,2-diamine) was determined and confirms the trans arrangement of the carboxylato ligands. Reduction potentials of the series of complexes reveal that replacement of equatorial chloro ligands by polyfluoroaryl ligands makes reduction substantially more difficult. They also confirm previously reported trends in that complexes having axial carboxylato ligands are more readily reduced than those having axial hydroxo ligands. Reduction potentials and in vitro activities showed no obvious correlations. Moderate to high activity was observed for many complexes in the series, including some of those that were very difficult to reduce.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626347     DOI: 10.1016/s0162-0134(99)00133-6

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  14 in total

1.  Antiproliferative Pt(IV) complexes: synthesis, biological activity, and quantitative structure-activity relationship modeling.

Authors:  Paola Gramatica; Ester Papa; Mara Luini; Elena Monti; Marzia B Gariboldi; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-06-06       Impact factor: 3.358

2.  Molecular and statistical modeling of reduction peak potential and lipophilicity of platinum(IV) complexes.

Authors:  James A Platts; Giuseppe Ermondi; Giulia Caron; Mauro Ravera; Elisabetta Gabano; Luca Gaviglio; Giorgio Pelosi; Domenico Osella
Journal:  J Biol Inorg Chem       Date:  2010-11-16       Impact factor: 3.358

Review 3.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

Review 4.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

5.  Interactions between mitochondria-damaging platinum(IV) prodrugs and cytochrome c.

Authors:  Amarasooriya M D S Jayawardhana; Yao-Rong Zheng
Journal:  Dalton Trans       Date:  2022-02-01       Impact factor: 4.390

6.  Heavy-Metal Trojan Horse: Enterobactin-Directed Delivery of Platinum(IV) Prodrugs to Escherichia coli.

Authors:  Chuchu Guo; Elizabeth M Nolan
Journal:  J Am Chem Soc       Date:  2022-07-08       Impact factor: 16.383

7.  Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties.

Authors:  Timothy C Johnstone; Nora Kulak; Eric M Pridgen; Omid C Farokhzad; Robert Langer; Stephen J Lippard
Journal:  ACS Nano       Date:  2013-05-22       Impact factor: 15.881

8.  Conjugated platinum(IV)-peptide complexes for targeting angiogenic tumor vasculature.

Authors:  Sumitra Mukhopadhyay; Carmen M Barnés; Ariel Haskel; Sarah M Short; Katie R Barnes; Stephen J Lippard
Journal:  Bioconjug Chem       Date:  2007-09-11       Impact factor: 4.774

Review 9.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

10.  In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.

Authors:  Ulrike Olszewski; Florian Ach; Ernst Ulsperger; Gerhard Baumgartner; Robert Zeillinger; Patrick Bednarski; Gerhard Hamilton
Journal:  Met Based Drugs       Date:  2009-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.